Home › Trial NCT02923180
Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer
- Trial IDNCT02923180
- StatusActive Not Recruiting
- PhasePhase 2
- Study typeInterventional
- SponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Enrollment33
- Start date2017-02-14
- ConditionsProstate Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.